Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats

Shock

Volumn 16, Issue 3, 2001, Pages 196-202

  Tofovic, Stevan P ^a,b   Zacharia, Lefteris ^a   Carcillo, Joseph A ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adenosine; Catecholamines; Endotoxemia; Heart; Renin; Tumor necrosis factor

Indexed keywords

1,3 DIPROPYL 8 (4 SULFOPHENYL)XANTHINE; 1,3-DIPROPYL-8-(4-SULFOPHENYL)XANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; 9-(2-HYDROXY-3-NONYL)ADENINE; ADENINE; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; CAFFEINE; CATECHOLAMINE; CYTOKINE; DRUG DERIVATIVE; ENDOTOXIN; ENZYME INHIBITOR; PROPRANOLOL; RENIN; XANTHINE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; ENDOTOXEMIA; HEART; HEART RATE; MALE; METABOLISM; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ADENINE; ADENOSINE; ADENOSINE DEAMINASE; ANIMALS; BLOOD PRESSURE; CAFFEINE; CATECHOLAMINES; CYTOKINES; ENDOTOXEMIA; ENDOTOXINS; ENZYME INHIBITORS; HEART; HEART RATE; MALE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; RENIN; XANTHINES;

EID: 0035464774     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200116030-00005     Document Type: Article

References (35)

1. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 43:R577-R595, 1998.
2. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated levels of tumor necrosis factor in severe heart failure. N Engl J Med 323:236-241, 1990.
3. Eichenholz P, Eichacker PQ, Hoffman WD, Banks SM, Parrilo JE, Danner RT, Natanson C: Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 263:H668-H675, 1992.
4. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL: Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-711, 1994.
5. Kubota T, McTiernan CF, Frye CS, Slawson SE, Koretsky AP, Demetris AJ, Feldman AM: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpresison of tumor necrosis factor-alpha. Cir Res 81:627-635, 1997.
6. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CG, Quintana PJE, Sabbadini RA: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98:2854-2865, 1996.
7. Gurevitch J, Frolkis I, Yuhas Y, Paz Y, Matsa M, Mohr R, Yakirevich V: Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 28:247-252, 1996.
8. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561, 1993.
9. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Tolerance DS, Otten-Evans C, Greenstreet T, Weerawarna K: Protection against a lethal dose of endotoxin by an inhibitor of TNF processing. Nature 370:218-220, 1994.
10. Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor loripram suppresses tumor necrosis factor-a production by human mononuclear cells. Intern J Immuno-Pharmacol 15:409-413, 1993.
11. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S: Enhanced: tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 25:147-153, 1995.
12. Bardenheuer H, Forts H, Haller M, Peter K: Influence of improved tissue oxygenation on plasma adenosine (ADO) in septic patients. Intensive Care Med 165:536, 1990.
13. Buouma MG, Stad RK, van der Wildenberg FA, Buurman WA: Differential regulatory effects of adenosine on cytokines release by activated human monocytes. J Immunol 153:4159-4168, 1994.
14. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW: Endogenous adenosine curtails lipopolysaccharide-stimulated tumor necrosis factor synthesis. Scand J Immunol 45:132-139, 1997.
15. Parmely MJ, Zhou WW, Edwards CK 3rd, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue seleclively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 151:389-396, 1993.
16. Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A: Protective effects of an adenosine kinase inhibitor in septic shock. J Immunol 152:5853-5859, 1994.
17. Wagner DR, McTiernan C, Sandres VJ, Feldman A: Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor in the failing human heart. Circulation 97:521-524, 1998.
18. Meldrum DR, Cain BS, Cleveland JC, Meng X, Ayala A, Banerjee A, Harken AH: Adenosine decreases post-ischemic myocardial TNFα production: antiinflammatory implications for preconditioning and transplantation. Immunology 92:472-477, 1997.
19. Tofovic SP, Kusaka I, Rominski B, Jackson EK: Caffeine increases renal renin secretion in a rat model of genetic heart failure. J Cardiovas Pharmacol 33: 440-450, 1999.
20. Jackson EK, Mi Z, Koehler MT, Carcillo JA, Herzer WA: A injured erythrocyte release adenosine deaminase into the circulation. J Pharmacol Exp Ther 279: 1250, 1996.
21. Tofovic SP, Kusaka I, Li P, Jackson EK: Effects of adenosine deaminase inhibition on blood pressure in old spontaneously hypertensive rats. Clin Exp Hypertension 20:329-344, 1998.
22. Tofovic SP, Branch KR, Oliver RD, Magee WD, Jackson EK: Caffeine potentiates vasodilator induced renin release. J Pharmacol Exp Ther 256:850-860, 1991.
23. Tofovic SP, Kusaka I, Pfeifer SA, Jackson EK: Central effects of caffeine on renal renin secretion and norepinephrine spillover. J Cardiovas Pharmacol 28:302-313, 1996.
24. Feostikov I, Biabbioni I. Adenosine A2B receptors. Pharmacol Rev 49:381-402, 1997.
25. Meng X, Ao L, Meldrum DR, Cain BS, Shames BD, Selzman CH, Banerjee A, Harkem AH: TNF-α and myocardial depression in endotoxin rats: temporal discordance of an obligatory relationship. Am J Physiol 1998.
26. Eichenholz PW, Eichancker PQ, Hoffman WD, Banks SM, Parrillo JE, Danner RL, Natanson C. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 263:H668-H675, 1992.
27. Pagani FD, Baker LS, Hsi C, Knox M, Fink M, Svisner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in coinscious dogs. J Clin Invest 90:389-398, 1992.
28. Murray DR and Freeman GL: Tumor necrosis factor α-induces biphasic effect on myocardial contractility in conscious dogs. Circ Res 78:154-160, 1996.
29. Sullivan GW, Luong LS, Carper HT, Barnes RC, Mandell GL.: Methylxanthines with adenosione alter TNFα-primed PMN activation. Immunopharmacology 31:19-29, 1995.
30. Pettifer ER, Labusi JM, Salter ED, Stam EJ, Cheng JB, Griffiths RJ: Regulation of tumor necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. Br J Pharmacol 117:1530-1534, 1996.
31. Monastra G, Secchi EF: Beta-adrenergic receptors mediate in vivo the adrenaline inhibition of lipopolysaccharide-induced tumor necrosis factor release. Immunol Lett 38:127-130, 1998.
32. Van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-α and potentiates production of interleukin 10 during human endotoxemia. J Clin Invest 97:713-719, 1996.
33. Jackson EK: Adenosine: a physiological brake on renin release. Ann Rev Pharmacol Toxicol 31:1-35, 1991.
34. Deray G, Branch RA, Jackson, EK: Methylxanthines augment the renin response to suprarenal-aortic constriciton. Naunyn Schmiedebergs Arch Pharmacol 339:690-696, 1989.
35. Tseng CJ, Kuan CJ, Chu H, Tung CS: Effect of caffeine treatment on plasma renin activity and angiotensin I concentrations in rats. Life Sci 52:883-890, 1993.